NCT01074086View on ClinicalTrials.gov

Phase I Study in RAD 001 Patients With Relapse AML

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

AML

Interventions

DRUG

RAD 001

RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg

Trial Locations (1)

75014

Sophie Park, Paris

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

French Innovative Leukemia Organisation

OTHER